Published on: 29 January 2018
In the “golden era” of antibiotic drug discovery – 1950 to 1970 – drug companies could afford to be choosy, selecting only the very best candidates for approval.As a result, many potent antibiotics did not make the cut for development and were abandoned. Given the current crisis in antibiotic discovery, the time is right to revisit many of these potentially invaluable molecules in search of antibiotic scaffolds with novel modes of action.